SH3BGRL confers innate drug resistance in breast cancer by stabilizing HER2 activation on cell membrane

BACKGROUND: HER2-positive breast cancer is usually associated to the more aggressive progression and the worse prognosis, but the mechanism underlying the innate resistance to HER2-targeted therapy remains elusive. The scaffold protein SH3-domain-binding glutamic acid-rich protein-like protein (SH3B...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Exp Clin Cancer Res
Prif Awduron: Li, Hui, Zhang, Mingming, Wei, Yanli, Haider, Farhan, Lin, Yitong, Guan, Wen, Liu, Yanbin, Zhang, Shaoyang, Yuan, Ronghua, Yang, Xia, Yang, Shulan, Wang, Haihe
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BioMed Central 2020
Pynciau:
Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7204297/
https://ncbi.nlm.nih.gov/pubmed/32381043
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-020-01577-z
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg